Background Sub-anaesthetic administration of ketamine is an emerging practice in patients
presenting treatment resistant depression (TRD), however several outstanding questions …

Ketamine, a drug introduced in the 1960s as an anesthetic agent and still used for that
purpose, has garnered marked interest over the past two decades as an emerging treatment …

Clinical studies provide evidence that ketamine and psilocybin could be used as fast-acting
antidepressants, though their mechanisms and toxicity are still not fully understood. To …

Accumulating evidence suggests that brain-derived neurotrophic factor (BDNF) is
associated with the pathophysiology of major depressive disorder (MDD). In this mini review …

Despite the continuous advancement in neurosciences as well as in the knowledge of
human behaviors pathophysiology, currently suicide represents a puzzling challenge. The …

Major depressive disorder (MDD) is a highly prevalent and disabling disorder. Despite the
many hypotheses proposed to understand the molecular pathophysiology of depression, it is …

Increasing evidence supports the rapid antidepressant effect of a low-dose ketamine
infusion in treatment-resistant depression (TRD). Proinflammatory cytokines play a crucial …

The emerging roles of ketamine and esketamine as effective rapid-acting antidepressants
hold promise for patients suffering from treatment-resistant depression and/or major …

Objectives: Extant evidence indicates that ketamine exerts rapid antidepressant effects in
treatment-resistant depressive (TRD) symptoms as a part of major depressive disorder …

Ketamine Toxicity - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe
PMC Menu About Tools Developers Help Contact us Helpdesk Feedback Twitter Blog Tech …